In humans and other animals, signals from a central circadian clock in the brain generate the seasonal and daily rhythms of life. They help the body to prepare for expected changes in the environment and also optimize when to sleep, eat and do other daily activities. Scientists at Washington University in St. Louis are working […]
Tag: Steven Mennerick
Mennerick named director of Division of Biology & Biomedical Sciences
Neuroscientist Steven Mennerick, PhD, a dedicated mentor and the John P. Feighner Professor of Neuropsychopharmacology at Washington University School of Medicine in St. Louis, has been named director and associate dean of the university’s Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS). Mennerick had been serving as the interim associate dean since December 2020 and […]
Mennerick receives NIH grant
Steven J. Mennerick, PhD, the John P. Feighner Professor of Neuropsychopharmacology and a professor of neuroscience at the School of Medicine, received a five-year $2.3 million grant from the National Institute of Mental Health of the National Institutes of Health (NIH) for research titled “GABAA receptor populations in hippocampus and thalamus.” Originally published on The […]
$12.2 million to fund new Conte Center to study neurosteroids
The National Institute of Mental Health (NIMH) has awarded Washington University School of Medicine in St. Louis a five-year, $12.2 million grant to create a center aimed at advancing research into neurosteroids as treatments for depression and other psychiatric disorders. The new Silvio O. Conte Center for Basic Neuroscience Research will be one of only […]
On the frontiers of psychiatry
Physician-scientists aim to reduce the impact of mental illness on society From the WashU Outlook Magazine… Up to one-third of the 16 million Americans with clinical depression don’t get relief from antidepressant drugs. As a result, they endure continuing sadness, problems with sleep, and often, difficulty concentrating, so that reading a book or functioning at […]
New approach to developing antidepressants
CRISPR technology helps target mood-boosting receptors in brain From the WashU School of Medicine News… An estimated 13 percent of Americans take antidepressant drugs for depression, anxiety, chronic pain or sleep problems. For the 14 million Americans who have clinical depression, roughly one third don’t find relief with antidepressants. But now, researchers at Washington University […]